Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rozanolixizumab in Pediatric Generalized Myasthenia Gravis
NCT06149559Phase 3Completed
- Sponsor
- UCB
- Start
- Jun 2024
- Primary completion
- Oct 2026
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
A Phase 3 trial of rozanolixizumab in myasthenia gravis (MG), sponsored by UCB. Started Jun 2024; status: completed.
02
Drugs
rozanolixizumab
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT06149559.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06149559.